Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel

Purpose: The purpose of this study was to identify the drug resistant role of miR-224 expression in cervical cancer. Materials and Methods: The expression of miR-224 pre- and post-paclitaxel treatment was determined by using stem-loop real-time reverse transcription polymerase chain reaction (RT-PCR). The authors exogenously upregulated miR-224 expression in SiHa cells using miRIDIAN miR-224 mimic transfection and observed its impact on paclitaxel sensitivity using Cytotoxicity assays. Results: MiR-224 was significantly downregulated with fold values at 2.130435 and 4.26087 under five and ten nM paclitaxel treatments, respectively. MiR- 224 expression is markedly increased in SiHa cells after transfected with miRIDIAN miR-224 mimic. Exogenous miR-224 facilitates paclitaxel sensitivity in cervical cancer cells. The IC50 value was decreased in SiHa with overexpression of miR-224 compared with miRNA-negative control (p < 0.0001). Conclusion: The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy.

miR-224; Chemo-resistance; Cervical cancer; Paclitaxel.

[1] Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., et al.: “Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance”. Drug Resist. Updat., 2010, 13, 109.

[2] Li H., Yang B.B.: “Friend or foe: the role of microRNA in chemotherapy resistance”. Acta Pharmacol. Sin., 2013, 34, 870.

[3] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global Cancer Statistics”. CA Cancer J. Clin., 2011, 61, 69.

[4] Rojas-Espaillat L.A., Rose P.G.: “Management of locally advanced cervical cancer:”. Curr. Opin. Oncol., 2005, 17, 485.

[5] Mountzios G., Soultati A., Pectasides D., Pectasides E., Dimopoulos M.A., Papadimitriou C.A.: “Developments in the systemic treatment of metastatic cervical cancer”. Cancer Treat. Rev., 2013, 39, 430.

[6] Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., et al.: “MicroRNAs modulate the chemosensitivity of tumor cells”. Mol. Cancer Ther., 2008, 7, 1

[7] Torres A., Torres K., Maciejewski R., Harvey W.H.: “MicroRNAs and their role in gynecological tumors”. Med. Res. Rev., 2011, 31, 895.

[8] Pillai R.S., Bhattacharyya S.N., Filipowicz W.: “Repression of protein synthesis by miRNAs: how many mechanisms?” Trends Cell. Biol., 2007, 17, 118.

[9] Bartel D.P.: “MicroRNAs: target recognition and regulatory functions”. Cell, 2009, 136, 215.

[10] Garzon R., Calin G.A., Croce C.M.: “MicroRNAs in cancer”. Annu. Rev. Med., 2009, 60, 167.

[11] Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., et al.: “Involvement of human micro- RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines”. Gastroenterology, 2006, 130, 2113.

[12] Yang H., Kong W., He L., Zhao J.J., O’Donnell J.D., Wang J., et al.: “MicroRNA expression profiling in human ovarian cancer:miR- 214 induces cell survival and cisplatin resistance by targeting PTEN”. Cancer Res., 2008, 68, 425.

[13] Nordentoft I., Birkenkamp-Demtroder K., Agerbæk M., Theodorescu D., Ostenfeld M.S., Hartmann A., et al.: “miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer”. BMC Med. Genomics, 2012, 5, 40.

[14] Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., et al.: “MicroRNA- 21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol”. BMC Cancer, 2010, 10, 27.

[15] Shen Y., Wang P., Li Y., Ye F., Wang F., Wan X., et al.: “miR-375 is upregulated in acquired Paclitaxel resistance in cervical cancer”. Br. J. Cancer, 2013, 109, 92.

[16] Wang Y., Lee C.G.: “Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?” Epigenomics, 2011, 3, 235.

[17] Fu J., Tang W., Du P., Wang G., Chen W., Li J., et al.: “Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis”. BMC Syst. Biol., 2012, 6, 68.

[18] Christenson L.K.: “MicroRNA control of ovarian function”. Anim. Reprod., 2010, 7, 129.

[19] Scapoli L., Palmieri A., Lo Muzio L., Pezzetti F., Rubini C., Girardi A., et al.: “MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression”. Int. J. Immunopathol. Pharmacol., 2010, 23, 1229.

[20] Zhang Y., Takahashi S., Tasaka A., Yoshima T., Ochi H., Chayama K.: “Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma”. J. Gastroenterol. Hepatol., 2013, 28, 565.

[21] Allen K.E., Glen W.J.: “Resistance may not be futile: microRNA bio markers for chemoresistance and potential therapeutics”. Mol. Cancer Ther., 2010, 9, 3126

[22] Wu X., Xiao H.: “miRNAs modulate the drug response of tumor cells”. Sci. China C. Life Sci., 2009, 52, 797.

[23] Gottesman M.M.: “Mechanisms of cancer drug resistance”. Annu. Rev. Med., 2002, 53, 615.

[24] Zheng T., Want J., Chen S., Liu L.: “Role of microRNA in anticancer drug resistance”. Int. J. Cancer, 2009, 126, 2.

[25] Lui F.S.: “Mechanisms of chemotherapeutic drug resistance in cancer therapy – a quick review”. Taiwan J. Obstet. Gynecol., 2009, 48, 239

[26] Zhang X., Yashiro M., Qiu H., Nishii T., Matsuzaki T., Hirakawa K.: “Establishment and characterization of multidrug-resistant gastric cancer cell lines”. Anticancer Res., 2010, 30, 915.

[27] Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z.: “MicroRNAs modulate the chemosensitivity of tumor cells”. Mol. Cancer Ther., 2008, 7, 1.

[28] Altuvia Y., Landgraf P., Lithwick G., Elefant N., Pfeffer S., Aravin A., et al.: “Clustering and conservation patterns of human microRNAs”. Nucleic Acids Res., 2005, 33, 2697.

[29] Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., et al.: “A mammalian microRNA expression atlas based on small RNA library sequencing”. Cell, 2007, 129, 140.

[30] Gokhale A., Kunder R., Goel A., Sarin R., Moiyadi A., Shenoy A., et al.: “Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway”. J. Cancer Res. Ther., 2010, 6, 521.

[31] Pai R., Nehru G.A., Samuel P., Selvan B., Kumar R., Jacob P.M., et al.: “Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues”. Indian J. Pathol. Microbiol., 2012, 55, 158.

[32] Mees S.T., Mardin W.A., Sielker S., Willscher E., Senninger N., Schleicher C., et al.: “Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas”. Ann. Surg. Oncol., 2009, 16, 2339.

[33] Prueitt R.L., Yi M., Hudson R.S., Wallace T.A., Howe T.M., Yfantis H.G., et al.: “Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer”. Prostate, 2008, 68, 1152.

[34] Lichner Z., Mejia-Guerrero S., Ignacak M., Krizova A., Bao T.T., Girgis A.H., et al.: “Pleiotropic action of renal cell carcinoma dysregulated miRNAs on hypoxia-related signaling pathways’. Am. J. Pathol., 2012, 180, 167.

[35] Christenson L.K.: “MicroRNA control of ovarian function”. Anim. Reprod., 2010, 7, 129.

[36] Scapoli L., Palmieri A., Lo Muzio L., Pezzetti F., Rubini C., Girardi A., et al.: “MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression”. Int. J. Immunopathol. Pharmacol., 2010, 23, 1229.

[37] Rao Q., Shen Q., Zhou H., Peng Y., Li J., Lin Z.: “Aberrant microRNA expression in human cervical carcinomas”. Med. Oncol., 2012, 29, 1242

[38] Shen S.N., Wang L.F., Jia Y.F., Hao Y.Q., Zhang L., Wang H.: “Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer”. Diagn. Pathol., 2013, 8, 69.